Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Week 46

November 9 – 15, 2026 · 7 articles

Clinical · Molecular biology

Site-specific outcomes and genomics in metastatic pancreatic ductal adenocarcinoma

Yousef M, Chowdhury S, Albarouki S, et al.

The oncologist

This retrospective cohort study of 1,095 patients with metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates that the pattern of metastatic spread is strongly linked to clinical outcome and genomic detection. Patients with lung-only metastases had a significantly prolonged median overall survival of 57.6 months compared to roughly 19.5 months in patients with liver-involved disease. Tissue genomic profiling identified lower TP53 mutation frequencies and higher GNAS mutation rates in non-liver and lung-only metastases. Crucially, liquid biopsy (n = 240) showed markedly lower detection rates for KRAS (10%) and TP53 (23%) in lung-only disease, underscoring that tissue-based sequencing must be prioritized in these patients to guide KRAS-directed therapeutic decisions.

Molecular biology

Rising cell-free DNA level tracks cancer-associated methylation signal and improves multicancer detection

Basu S, Hiremath P, Rathod N, et al.

Proceedings of the National Academy of Sciences of the United States of America

Analyzing 1,480 untreated participants across 43 hospitals, this study challenges the assumption that elevated total circulating cell-free DNA (ccfDNA) merely dilutes tumor-derived DNA through immune-derived shedding. Instead, rising total ccfDNA levels are correlated with an enrichment of cancer-associated DNA methylation signals, independent of cancer type, clinical stage, or technical covariates. In fact, ccfDNA concentration explains more variance in methylation signal than cancer stage itself. Clinically, higher ccfDNA yields significantly increased multicancer detection sensitivity, rising from 0.55 in the lowest concentration tertile to 0.85 in the highest for stage I, and from 0.59 to 0.86 for stage II.

Bioinfo & AI

SomatiX: accurate and efficient somatic SNV detection from matched tumor-normal long-read DNA sequencing

Liu Z

Bioinformatics (Oxford, England)

SomatiX is a deep-learning tool designed for accurate somatic single-nucleotide variant (SNV) calling from matched tumor-normal long-read sequencing data across ONT and PacBio platforms. The method utilizes an allele-aware pileup representation to overcome sequencing noise, variable tumor purity, and low variant allele fractions (VAFs). Benchmarked across cancer cell line datasets, SomatiX outperformed DeepSomatic and ClairS in F1 scores on Oxford Nanopore data and matched performance on PacBio, reaching mean F1 scores of 0.986 and 0.988 on held-out chromosome 1 (for VAF ≥ 0.05 and ≥3 supporting reads). In addition to robust detection of low-VAF SNVs, it features a compact model architecture and the fastest runtime among evaluated tools.

Clinical · Molecular biology

The Use of TF-Ag-α to Selectively Capture Tumor-Derived Extracellular Vesicles and Enhance the Predictive Performance of Extracellular Vesicle PD-L1 for Response to Immune Checkpoint Inhibitors

Hsu CC, Qi M, Ito F, et al.

Cancer research communications

Assessing extracellular vesicle (EV) PD-L1 via liquid biopsy is an attractive non-invasive approach, but its predictive efficacy is confounded by non-tumor-derived EV background. To overcome this limitation, a novel assay selectively captured tumor-derived EVs (TEX) using the tumor-specific glycoantigen TF-Ag-α in serum from 91 NSCLC patients undergoing anti-PD-1 therapy. While baseline levels showed moderate performance (AUC 0.76), dynamic fold changes after the first treatment cycle revealed a ~4.18-fold increase in responders and a ~20% decrease in non-responders. This dynamic on-treatment metric delivered superior predictive power with an AUC of 0.93 (sensitivity 0.95, specificity 0.80), substantially outperforming both total EV PD-L1 and conventional tissue PD-L1.

Clinical · Molecular biology

Upfront Comprehensive Genomic Profiling in Advanced Biliary Tract Cancer: Real-World Implementation and Clinical Outcomes

Hussung S, Roth M, Akhoundova D, et al.

Cancer medicine

This real-world study evaluated the implementation of upfront comprehensive genomic profiling (CGP) in 80 patients with advanced biliary tract cancer (BTC). Clinically actionable alterations were detected in 52.5% of cases—predominantly in IDH1, FGFR2, ERBB2, KRAS G12C, and BRAF—with anatomical enrichment of FGFR2 and IDH1 in intrahepatic cholangiocarcinoma. Matched targeted therapies were administered to 11 of the 42 actionable patients, yielding a significantly longer treatment duration compared with the preceding systemic line (p = 0.0391) and enabling secondary surgical resection in two patients. These findings confirm the clinical feasibility and value of upfront CGP in BTC while emphasizing the critical need to bridge the gap between biomarker identification and drug access.

Clinical · Molecular biology

Spatial transcriptomics identifies tumor-intrinsic and stromal programs associated with immune exclusion in NSCLC

Guegan JP, Bonhomme B, Peyraud F, et al.

Signal transduction and targeted therapy

This study investigates the molecular and spatial mechanisms underlying CD8+ T-cell immune exclusion in patients with non-small cell lung cancer (NSCLC) treated with immune checkpoint blockade. Spatial CD8+ exclusion, defined by stroma-restricted T cells that fail to penetrate tumor nests, correlates with reduced objective response rates and shorter progression-free survival. Multi-omic integration—including GeoMx spatial transcriptomics, multiplex immunofluorescence, and bulk transcriptomics—revealed tumor-intrinsic defects in antigen-presentation machinery, specifically involving HLA class I genes and TAP1, along with uncoupled IFN-γ signaling. Concurrently, the excluded stroma is characterized by myofibroblastic cancer-associated fibroblasts and collagen-dense barriers, accompanied by CD8+ T cells displaying impaired metabolic activation and lower TCR diversity rather than classic exhaustion.

Clinical

Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD

Goldman JW, Riess JW, Cho BC, et al.

Clinical lung cancer

The phase II ORCHARD platform study evaluated the efficacy and safety of osimertinib combined with carboplatin and pemetrexed in patients with EGFR-mutated advanced non-small cell lung cancer (NSCLC) who progressed on first-line osimertinib monotherapy. Among 31 treated patients, the confirmed objective response rate was 26%, with a median duration of response of 7.6 months. Median progression-free survival reached 5.6 months, while median overall survival was 10.9 months. Grade ≥ 3 adverse events occurred in 65% of patients, leading to treatment discontinuation in 23%. These findings suggest that continuing osimertinib alongside platinum-based doublet chemotherapy offers modest clinical benefit post-progression.